Cargando…

P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS

Detalles Bibliográficos
Autores principales:	Jeyaraju, Danny, Hayati, Sheida, Polonskaia, Ann, Browne, Andrew, Risueño, Alberto, Hagner, Patrick, Gupta, Vikas, Talpaz, Moshe, Hernandez, Christopher, Chia, Vincent, Brown, Patrick, De Menezes, Daniel Lopes, La Motte-Mohs, Ross, Nvs Suragani, Rajasekhar, Gandhi, Anita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431518/ http://dx.doi.org/10.1097/01.HS9.0000970892.97539.5e

Ejemplares similares

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
por: Harrison, Claire N., et al.
Publicado: (2020)

P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
por: Talpaz, Moshe, et al.
Publicado: (2020)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
por: Gupta, V., et al.
Publicado: (2022)

P1057: REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE
por: Harrison, C., et al.
Publicado: (2022)

P1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS
por: Abraham, P., et al.
Publicado: (2022)

P1058: REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION
por: Passamonti, F., et al.
Publicado: (2022)

Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
por: Jamieson, Catriona, et al.
Publicado: (2015)

Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial
por: Harrison, Claire N., et al.
Publicado: (2021)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures
por: Singer, Jack W., et al.
Publicado: (2019)

P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY
por: Aluri, Srinivas, et al.
Publicado: (2023)

P1060: REAL-WORLD CLINICAL OUTCOMES AFTER 3 AND 6 MONTHS OF TREATMENT WITH FEDRATINIB FOLLOWING RUXOLITINIB FAILURE
por: Mascarenhas, J., et al.
Publicado: (2022)

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence
por: Harrison, Claire N., et al.
Publicado: (2016)

P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL
por: Lopes De Menezes, Daniel, et al.
Publicado: (2023)

P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS
por: Lopes De Menezes, Daniel, et al.
Publicado: (2023)

P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
por: Gupta, V., et al.
Publicado: (2022)

Clinical Utility of Fedratinib in Myelofibrosis
por: Waksal, Julian A, et al.
Publicado: (2021)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
por: Gangat, Naseema, et al.
Publicado: (2023)

Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
por: Talpaz, Moshe, et al.
Publicado: (2018)

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts
por: Harrison, Claire N., et al.
Publicado: (2022)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

Lute suites, BWV 996 & 997 Lautensuiten /
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1983)

Humor norms for 4,997 English words
por: Engelthaler, Tomas, et al.
Publicado: (2017)

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
por: Pardanani, A, et al.
Publicado: (2015)

The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis
por: Palmer, Jeanne, et al.
Publicado: (2020)

S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY
por: Ayala, Rosa, et al.
Publicado: (2023)

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial
por: Mesa, Ruben A., et al.
Publicado: (2021)

997. Protection of Unvaccinated Individuals by Influenza Vaccine Coverage of Household Contacts
por: Malosh, Ryan E, et al.
Publicado: (2018)

Revealing CO(2) dissociation pathways at vicinal copper (997) interfaces
por: Kim, Jeongjin, et al.
Publicado: (2023)

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
por: Ogasawara, Ken, et al.
Publicado: (2019)

Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults
por: Chen, Yizhe, et al.
Publicado: (2022)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
por: Kremyanskaya, Marina, et al.
Publicado: (2023)

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS
por: Kiladjian, J.-J., et al.
Publicado: (2022)

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023)

997. RLS-0071 Improves Survival in a Rat Model of Intestinal Necrosis
por: Cunnion, Kenji, et al.
Publicado: (2021)

Ruxolitinib for the Treatment of Essential Thrombocythemia
por: Gunawan, Arief, et al.
Publicado: (2018)

Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent
por: Lickliter, J D, et al.
Publicado: (2010)

997 Saliva vs Urine PCR: The Ideal Sample for congenital CMV Screening and Diagnosis
por: Pinninti, Swetha G., et al.
Publicado: (2014)

Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity
por: Teng, Yong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lamfe6of57o2mafs4184f7lfub